Celldex Therapeutics reported $456.23M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -6.66B 3.39B Mar/2026
Agenus USD -221.22M 49.89M Mar/2026
Amgen USD 9.19B 532M Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Celldex Therapeutics USD 456.23M 70.94M Mar/2026
Glaxosmithkline GBP 22.06B 360M Dec/2025
Nektar Therapeutics USD 89.83M 4.75M Dec/2025
Northwest Biotherapeutics USD -108.65M 8.26M Sep/2025
Pfizer USD 90.1B 3.63B Mar/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Roche Holding CHF 33.8B 758M Dec/2025